A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Active not recruiting 54 enrolled Dana-Farber Cancer Institute Genentech, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Timeline

Start: 2015-12
Primary completion: 2020-03
Completion: 2027-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ibrutinib	Small molecule	—	Oral
Subject	Obinutuzumab	Monoclonal antibody	—	—

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Summary

Timeline

Drugs

Indications